Literature DB >> 23594429

Two-center observational study of the accuracy of a Bayes Network for short-term outcome prediction in cholecystectomy patients.

Andrej Udelnow1, Agnes Schmidt, Rainer Muche, Doris Henne-Bruns, Peter Würl, Hans Lippert.   

Abstract

BACKGROUND: A Bayes Network was developed for individual risk prediction after cholecystectomy. Validity and robustness were compared with logistic regression analysis (LR).
METHODS: Clinical databases were created at the Ulm University and St. Franziskus Flensburg hospitals between 2001 and 2010 were comprised of hospitalized cholecystolithiasis patients serving as model and test cohorts, respectively. The probabilities of in-hospital death, prolonged hospitalization (>7 days), relaparotomy and erythrocyte transfusions were predicted based solely on admission data by BN and LR. ROC curves were calculated.
RESULTS: The Ulm and Flensburg cohorts consisted of 1,029 and 1,842 patients, respectively. The areas under the ROC curves for predicting death were 94% (p = 0.8) for both BN and LR, 70 vs. 76% (p < 0.001) for prolonged hospitalization, 69 vs. 68% (p = 0.8) for relaparotomy, and 84 vs. 78% (p = 0.1) for ET. Predictability declined for both methods when explanatory values were changed randomly. In contrast to LR, the BN revealed a good robustness to missing values.
CONCLUSION: Both BN and MR predicted the death risk quite accurately. The advantage of BN consists of its robustness to missing values. Moreover, its graphical representation may be helpful for clinical decision making.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2013        PMID: 23594429     DOI: 10.1159/000348670

Source DB:  PubMed          Journal:  Dig Surg        ISSN: 0253-4886            Impact factor:   2.588


  1 in total

1.  Analysis of prognostic factors for survival after surgery for gallbladder cancer based on a Bayesian network.

Authors:  Zhi-Qiang Cai; Peng Guo; Shu-Bin Si; Zhi-Min Geng; Chen Chen; Long-Long Cong
Journal:  Sci Rep       Date:  2017-03-22       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.